Cardiovascular Risk in Gout Patients Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)

被引：1
|
作者：
Mueller-Wieland, D. [1 ]
Nitschmann, S. [1 ]
机构：
[1] Univ Klinikum RWTH Aachen, Med Klin 1, Pauwelsstr 30, D-52074 Aachen, Germany
来源：
INTERNIST | 2018年 / 59卷 / 11期
关键词：
URIC-ACID;
D O I：
10.1007/s00108-018-0486-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1224 / 1228
页数：5
相关论文
共 50 条
  • [1] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    INTERNIST, 2020, 61 (05): : 530 - 532
  • [2] CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
    White, William B.
    Chohan, Saima
    Dabholkar, Aruna
    Hunt, Barbara
    Jackson, Robert
    AMERICAN HEART JOURNAL, 2012, 164 (01) : 14 - 20
  • [3] The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?
    Katsiki, Niki
    Borghi, Claudio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1853 - 1856
  • [4] Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
    White, William B.
    Saag, Kenneth G.
    Becker, Michael A.
    Borer, Jeffrey S.
    Gorelick, Philip B.
    Whelton, Andrew
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1200 - 1210
  • [5] Febuxostat vs allopurinol for gout: cardiovascular safety
    Reactions Weekly, 2021, 1858 (1) : 9 - 9
  • [6] Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
    Guan, Xudong
    Zhang, Shengzhao
    Liu, Jiayan
    Wu, Fengbo
    Zhou, Lingyan
    Liu, Ying
    Su, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
    Saag, Kenneth
    Becker, Michael A.
    White, William B.
    Whelton, Andrew
    Borer, Jeffrey
    Gorelick, Philip
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [8] Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia
    Ghossan, Roba
    Tabesh, Ouidade Aitisha
    Fayad, Fouad
    Richette, Pascal
    Bardin, Thomas
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (02) : e46 - e53
  • [9] UPDATE ON COMPARATIVE CARDIOVASCULAR SAFETY OF FEBUXOSTAT VERSUS ALLOPURINOL AMONG PATIENTS WITH GOUT
    Shin, A.
    Ha, Y. J.
    Lee, Y. J.
    Lee, E. B.
    Kang, E. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 385 - 385
  • [10] CARDIOVASCULAR EVENT ASSOCIATED WITH INITIATING ALLOPURINOL AND FEBUXOSTAT - ACUTE GOUT ATTACK AND CARDIOVASCULAR GOUT ATTACK
    Kim, H. J.
    Ahn, H. S.
    Kim, J.
    Ghang, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 106 - 106
12345